The influence of concomitant drug therapy on the efficacy of atrial overdrive stimulation for prevention of atrial tachyarrhythmias

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 1 II, 2003, Pages 272-277

  Konz, Karl Heinz ^a   Danilovic, Dejan ^b   Brachmann, Johannes ^c   Attuel, Patrick ^d   El Allaf, Dia ^e   John, Cornelia ^f   Malinowski, Klaus ^g   Le Blanc, Ulrich ^h   Szendey, Istvan ^a   Schibgilla, Volker ^c   Motzke, Thomas ^b  

^a Krankenhaus St Franziskus   (Germany)

^b Biotronik GmbH and Co KG   (Germany)

^c Medical Clinic II   (Germany)

^d Ctr Medico Chirurgical Parly 2   (France)

^e Centre Hospitalier Hutois   (Belgium)

^f Health Forum Dresden   (Germany)

^g Helios Clinics   (Germany)

^h Dueren Hospital gGmbH   (Germany)

Author keywords

Atrial fibrillation; Atrial overdrive pacing; Atrial tachyarrhythmia; Preventive pacing antiarrhythmic drug; Sotalol; adrenergic blocker

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DILTIAZEM; FLECAINIDE; METOPROLOL; MEXILETINE; NEBIVOLOL; NIFEDIPINE; PROPAFENONE; SOTALOL; VERAPAMIL;

ADULT; AGED; ALGORITHM; ARTIFICIAL HEART PACEMAKER; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

EID: 0347926099     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00031.x     Document Type: Conference Paper

References (9)

1. 2 CLS Pacemakers" study investigators. Therapy and prevention of atrial fibrillation by overdrive stimulation? Herzschrittmacher 2000; 20:104-111.
2. Konz KH, Szendey I, El Allaf D, et al. Efficacy of DDD+ mode in the prevention of paroxysmal atrial tachyarrhythmias: Interim results of a multicenter European study. Prog Biomed Res 2001; 6:269-275.
3. Camm AJ, Al-Saady NM, Opie LH. Antiarrhythmic agents. In LH Opie, JG Bernard (eds.): Drugs for the Heart. 5th ed. Philadelphia, PA, W.B. Sounders Company, 2001, pp. 221-272.
4. Opie LH, Yusuf S. Beta-blocking agents. In LH Opie, JG Bernard (eds.): Drugs for the Heart. 5th ed. Philadelphia, PA, W.B. Sounders Company, 2001, pp. 1-32.
5. Fuster V, Ryden L, Singer RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22:1852-1923.
6. Delfaut P, Saksena S, Prakash A, et al. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site RAal pacing for arrhythmia prevention. J Am Coll Cardiol 1998; 32:1900-1908.
7. Murgatroyd FD, Nitzsche R, Slade AK, et al. A new pacing algorithm for overdrive suppression of atrial fibrillation. Chorus Multicentre Study Group. PACE 1994; 17:1966-1973.
8. Ricci R, Santini M, Puglisi A, et al. Impact of consistent atrial pacing algorithm on the number of premature atrial complexes and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: A randomized prospective cross over study. J Interv Card Electrophysiol 2001; 5:33-44.
9. Waktare JEP, Hnatkova K, Sopher SM, et al. The role of atrial ectopics in initiating paroxysmal atrial fibrillation. Eur Heart J 2001; 22:333-339.